Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular
Free webinar: Telepathology: is there added value in LMICs?
Free webinar: Telepathology: is there added value in LMICs?

Tailoring therapy for leukaemia patients

Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA
Tailoring therapy for leukaemia patients ( Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA )
3 Dec 2016

TKI cessation for CML patients with deep molecular response: an update from the EURO-SKI trial

Dr Francois-Xavier Mahon - Université Bordeaux, Bordeaux, France
TKI cessation for CML patients with deep molecular response: an update from the EURO-SKI trial ( Dr Francois-Xavier Mahon - Université Bordeaux, Bordeaux, France )
3 Dec 2016

Dose reduction of TKIs for CML patients with deep molecular response

Prof Mhairi Copland - University of Glasgow, Glasgow, UK
Dose reduction of TKIs for CML patients with deep molecular response ( Prof Mhairi Copland - University of Glasgow, Glasgow, UK )
3 Dec 2016

Updates from the EURO-SKI trial of tyrosine kinase cessation

Dr Francois-Xavier Mahon - Université Bordeaux, Bordeaux, France
Updates from the EURO-SKI trial of tyrosine kinase cessation ( Dr Francois-Xavier Mahon - Université Bordeaux, Bordeaux, France )
3 Dec 2016

Incidence and risk factors for central venous catheter related thrombosis in children

Dr Julie Jaffray - Children's Center for Cancer, Los Angeles, USA
Incidence and risk factors for central venous catheter related thrombosis in children ( Dr Julie Jaffray - Children's Center for Cancer, Los Angeles, USA )
3 Dec 2016

CML patients with stable response may safely decrease dose of TKI

Prof Mhairi Copland - University of Glasgow, Glasgow, UK
CML patients with stable response may safely decrease dose of TKI ( Prof Mhairi Copland - University of Glasgow, Glasgow, UK )
3 Dec 2016

Novel antibody boosts responses in newly diagnosed AML

Prof Harry Erba - UAB Comprehensive Cancer Center, Birmingham, USA
Novel antibody boosts responses in newly diagnosed AML ( Prof Harry Erba - UAB Comprehensive Cancer Center, Birmingham, USA )
3 Dec 2016

Vadastuximab talirine in combination for newly diagnosed AML

Prof Harry Erba - UAB Comprehensive Cancer Center, Birmingham, USA
Vadastuximab talirine in combination for newly diagnosed AML ( Prof Harry Erba - UAB Comprehensive Cancer Center, Birmingham, USA )
3 Dec 2016

Remissions following anti-CD22 CAR therapy in children with relapsed ALL

Dr Terry Fry - National Cancer Institute, Bethesda, USA
Remissions following anti-CD22 CAR therapy in children with relapsed ALL ( Dr Terry Fry - National Cancer Institute, Bethesda, USA )
3 Dec 2016

Subgroup analysis of elderly high risk AML patients receiving CPX-351

Prof Jeffery Lancet - H. Lee Moffitt Cancer Center, Tampa, USA
Subgroup analysis of elderly high risk AML patients receiving CPX-351 ( Prof Jeffery Lancet - H. Lee Moffitt Cancer Center, Tampa, USA )
3 Dec 2016

A new spin on leukaemia therapy

Prof Armand Keating - University of Toronto, Toronto, Canada
A new spin on leukaemia therapy ( Prof Armand Keating - University of Toronto, Toronto, Canada )
3 Dec 2016

Anti CD22 CAR T cell therapy for relapsed paediatric ALL

Dr Nirali Shah - National Cancer Institute, Bethesda, USA
Anti CD22 CAR T cell therapy for relapsed paediatric ALL ( Dr Nirali Shah - National Cancer Institute, Bethesda, USA )
3 Dec 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation